Bonesupport Holding AB (publ) (BOEUF)
USD 32.55
(-2.11%)
USD 32.55
(-2.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 28.93 Million SEK | 159.38% |
| 2022 | -54.34 Million SEK | 25.3% |
| 2021 | -72.39 Million SEK | 19.76% |
| 2020 | -90.09 Million SEK | 39.68% |
| 2019 | -150.27 Million SEK | 12.73% |
| 2018 | -172.25 Million SEK | -56.97% |
| 2017 | -109.7 Million SEK | -14.4% |
| 2016 | -96.57 Million SEK | -92.38% |
| 2015 | -49.82 Million SEK | -14.89% |
| 2014 | -43.34 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 27.7 Million SEK | 1391.92% |
| 2024 Q3 | 42.83 Million SEK | 41.93% |
| 2024 Q2 | 31.61 Million SEK | 8.94% |
| 2023 Q4 | 7.21 Million SEK | -57.01% |
| 2023 Q2 | 7.82 Million SEK | 216.84% |
| 2023 Q1 | 2.47 Million SEK | 117.45% |
| 2023 Q3 | 16.78 Million SEK | 114.33% |
| 2023 FY | - SEK | 159.38% |
| 2022 FY | - SEK | 25.3% |
| 2022 Q1 | -14.89 Million SEK | 16.31% |
| 2022 Q2 | -12.98 Million SEK | 12.83% |
| 2022 Q4 | -14.16 Million SEK | -15.13% |
| 2022 Q3 | -12.29 Million SEK | 5.28% |
| 2021 Q1 | -17.59 Million SEK | 24.63% |
| 2021 Q4 | -17.8 Million SEK | -47.2% |
| 2021 Q3 | -12.09 Million SEK | 51.45% |
| 2021 Q2 | -24.9 Million SEK | -41.6% |
| 2021 FY | - SEK | 19.76% |
| 2020 Q3 | -17.69 Million SEK | 24.62% |
| 2020 Q4 | -23.33 Million SEK | -31.9% |
| 2020 Q1 | -29.2 Million SEK | 24.14% |
| 2020 Q2 | -23.47 Million SEK | 19.63% |
| 2020 FY | - SEK | 39.68% |
| 2019 Q2 | -47.82 Million SEK | -22.63% |
| 2019 Q4 | -38.5 Million SEK | -17.78% |
| 2019 Q1 | -38.99 Million SEK | 14.73% |
| 2019 FY | - SEK | 12.73% |
| 2019 Q3 | -32.68 Million SEK | 31.64% |
| 2018 Q3 | -57.11 Million SEK | -51.02% |
| 2018 Q1 | -33.13 Million SEK | 26.32% |
| 2018 FY | - SEK | -56.97% |
| 2018 Q4 | -45.73 Million SEK | 19.93% |
| 2018 Q2 | -37.82 Million SEK | -14.16% |
| 2017 Q1 | -27.43 Million SEK | 26.99% |
| 2017 FY | - SEK | -14.4% |
| 2017 Q4 | -44.96 Million SEK | -123.56% |
| 2017 Q3 | -20.11 Million SEK | -9.55% |
| 2017 Q2 | -18.36 Million SEK | 33.07% |
| 2016 Q4 | -37.57 Million SEK | -45.29% |
| 2016 Q2 | -20.82 Million SEK | -52.46% |
| 2016 Q1 | -13.66 Million SEK | 0.0% |
| 2016 FY | - SEK | -92.38% |
| 2016 Q3 | -25.86 Million SEK | -24.18% |
| 2015 FY | - SEK | -14.89% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 3101.907% |
| Ansell Limited | 209.86 Million USD | 86.211% |
| Ansell Limited | 206.3 Million USD | 85.973% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 42.83 Million USD | 32.453% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 1880.792% |
| Psykey, Inc. | -1.29 Million USD | 2333.993% |
| ConvaTec Group Plc | 455.5 Million USD | 93.647% |
| ConvaTec Group Plc | 455.5 Million USD | 93.647% |
| Encision Inc. | -544.19 Thousand USD | 5417.395% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 20505.472% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 26423.115% |
| Innovative MedTech Inc. | -7.67 Million USD | 477.087% |
| LifePoint, Inc. | -14.2 Million USD | 303.751% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 567.706% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 9003.692% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -215.23 Thousand USD | 13544.437% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 7231.134% |
| SmileDirectClub, Inc. | -186.13 Million USD | 115.546% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | 93.538% |
| SheerVision, Inc. | -110.53 Thousand USD | 26279.986% |
| United Health Products, Inc. | -2.5 Million USD | 1256.456% |
| Vasamed, Inc. | -4.57 Million USD | 732.58% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 1379.981% |
| Yubo International Biotech Limited | -1.17 Million USD | 2557.107% |